(Q33373922)

English

Pseudomembranous colitis following bortezomib therapy in a myeloma patient

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pseudomembranous colitis following bortezomib therapy in a myeloma patient (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

object named as

Dong-Gun Lee

3

0 references

author name string

Sung-Jin Moon

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chang-Ki Min

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Seok Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jong-Wook Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Woo-Sung Min

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chun-Choo Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Myungshin Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gyeongsin Park

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Younggu Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

18 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Acta Haematologica

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

211-214

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

1 reference

https://api.crossref.org/works/10.1159%2F000098699

21 January 2018

Identifiers

10.1159/000098699

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33373922&oldid=1968182777"